BHC · Bausch Health Companies Inc.
$6.89
-0.04 (-0.58%)
At close · Aug 19
Market Cap
$2.59B
Shares
373.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.89
Open$6.99
Day$6.72–7.08
52W close$4.43–7.90
Avg vol 30d4.3M
Short int7.6M · 2.0% float · 1.5d
Short vol69%
Last earningsJul 29, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+30%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
71%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+51%
trailing
6-month return
+14%
trailing
YTD return
−1%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.02% of float · ▲ +2.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
225 holders — mid 3-yr range
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
−10%
Y/Y
EPS growth
+423%
Y/Y
Free cash flow
$1.0B
Balance sheet
$19.5B
net debt
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Revenue growth vs. Prior Year - BHC (excl. B+L)
· full year 2026
Initiated
4% – 6%
Adjusted EBITDA (in Billions)
· full year 2026
Non-GAAP
Initiated
$4.05B – $4.18B
Adjusted EBITDA (in Billions) - B+L
· full year 2026
Non-GAAP
Initiated
$1.03B – $1.08B
Adjusted EBITDA (in Billions) - BHC (excl. B+L)
· full year 2026
Non-GAAP
Initiated
$3.03B – $3.1B
Adjusted EBITDA growth vs. Prior Year - BHC (excl. B+L)
· full year 2026
Non-GAAP
Initiated
8% – 11%
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Revenue
· full year
$5B – $5.1B
Adjusted EBITDA (excluding the impact of core IP R&D)
· full year
$2.7B – $2.75B
Adjusted operating cash flow
· full year
$975M – $1.03B
Guided vs delivered
· last 2 settled
Revenues
2024
guided $4.7B – $4.85B
$9.63B
Beat +101.6%
Revenues for Bausch Health excluding B&L
full-year 2023
guided $4.55B – $4.63B
$8.76B
Beat +90.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
71%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.02% of float · ▲ +2.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
225 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $7 · 71%
Range high $8
vs 200-day avg +18%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted cash flows from operations (non-GAAP) non-GAAP | $1.01B | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) non-GAAP | $1.97B | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) non-GAAP | $1.91B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Consolidated Adjusted Net Income Attributable to Bausch Health (non-GAAP) non-GAAP | $476M | second quarter of 2026 | — |
|
|
|||
| Organic Revenue (Non-GAAP) Change non-GAAP | 9% | Six Months Ended June 30, 2026 | — |
| Adjusted Cash Flow from Operations non-GAAP | $1.2B | Full-Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BHC
this stock
Bausch Health Companies Inc.
|
$2.59B | -0.9% | -9.8% | — | 2.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.75B | +17.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +4.0% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BHC | +11.0% | +51.1% | +14.1% | +0.0% | -0.9% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +11.4% | +48.2% | +2.5% | -3.0% | -13.6% |
Key facts
CIK
885590
CUSIP
071734107
13F (30d)
206 filings
205 filers
Visit website
Investor relations